Holen Sie sich die Stockscreener-App
3.50
1.69%
-0.06
Handel nachbörslich:
3.51
0.010
+0.29%
Schlusskurs vom Vortag:
$3.56
Offen:
$3.6
24-Stunden-Volumen:
101.67K
Relative Volume:
0.53
Marktkapitalisierung:
$179.78M
Einnahmen:
$63.69M
Nettoeinkommen (Verlust:
$-44.82M
KGV:
-1.75
EPS:
-2
Netto-Cashflow:
$-30.56M
1W Leistung:
-7.65%
1M Leistung:
-0.28%
6M Leistung:
+44.03%
1J Leistung:
+83.25%
1-Tages-Spanne:
$3.50
$3.74
1-Wochen-Bereich:
$3.50
$3.94
52-Wochen-Spanne:
$1.35
$5.33
Mdxhealth Sa Stock (MDXH) Company Profile
Firmenname
Mdxhealth Sa
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MDXH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDXH
Mdxhealth Sa
|
3.50 | 182.86M | 63.69M | -44.82M | -30.56M | -2.00 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Mdxhealth Sa Stock (MDXH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Eingeleitet | Craig Hallum | Buy |
| 2024-10-31 | Eingeleitet | Lake Street | Buy |
| 2023-05-31 | Eingeleitet | TD Cowen | Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Mdxhealth Sa Aktie (MDXH) Neueste Nachrichten
MDxHealth SA (NASDAQ:MDXH) Short Interest Update - MarketBeat
MDxHealth SA (NASDAQ:MDXH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Midday Stock Roundup: MDxHealth Up 9% Since Preliminary Q4, FY Results - Orange County Business Journal
Analysts Expect Breakeven For MDxHealth SA (NASDAQ:MDXH) Before Long - Sahm
MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest - MarketBeat
Retail Surge: How interest rate cuts could boost MDxHealth SA stockSwing Trade & Community Trade Idea Sharing Platform - Bộ Nội Vụ
MDxHealth Posts Preliminary 2025 Results, Expects Revenue Growth Of 26% To 28% In 2026 - Nasdaq
MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance By Investing.com - Investing.com India
MDxHealth Sees Over 20% Revenue Growth in Q4, Full Year - Orange County Business Journal
MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance - Investing.com
MDXH Projects Strong Revenue Growth and Ambitious 2026 Targets - GuruFocus
MDxHealth sees Q4 revenue $30.5M, consensus $26.18M - TipRanks
MDxHealth Posts Strong 2025 Revenue Growth, Sets 2026 Outlook and Revises Exact Sciences Earnout - TipRanks
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences - The Manila Times
Redlands Daily Facts - FinancialContent
MDxHealth (NASDAQ:MDXH) and Biotricity (OTCMKTS:BTCY) Critical Survey - Defense World
How MDxHealth SA stock reacts to job market data2025 Geopolitical Influence & Technical Entry and Exit Tips - ulpravda.ru
Will MDxHealth SA stock attract ESG investors2025 Big Picture & Proven Capital Preservation Methods - ulpravda.ru
Analyst Downgrade: How MDxHealth SA stock reacts to inflationary pressures2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Is MDxHealth SA stock dividend yield sustainableWeekly Market Report & Consistent Income Trade Ideas - Улправда
How MDxHealth SA stock reacts to inflationary pressuresTrade Analysis Summary & AI Forecast for Swing Trade Picks - Улправда
Can MDxHealth SA stock resist sector downturnsJuly 2025 Fed Impact & Capital Protection Trade Alerts - Улправда
MDxHealth announces next phase of collab with University of Oxford - MSN
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term - Yahoo Finance
MDxHealth SAOrdinary Shares (NQ: MDXH - FinancialContent
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer - The Manila Times
World’s largest prostate cancer trial adds genomic test to guide care - Stock Titan
MDxHealth SA (NASDAQ:MDXH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MDxHealth SA (NASDAQ:MDXH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
MDxHealth Files to Sell Up to $200 Million in Shares - marketscreener.com
MDxHealth SA to offer securities up to $200 millionSEC filing - marketscreener.com
Setup Watch: Will MDxHealth SA stock continue dividend increasesWeekly Trend Recap & Expert Verified Movement Alerts - Bộ Nội Vụ
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
MDXH: BTIG Reiterates Buy Rating with $7 Price Target | MDXH Sto - GuruFocus
BTIG reiterates Buy rating on MDxHealth stock, maintains $7 price target By Investing.com - Investing.com South Africa
BTIG Research Reaffirms "Buy" Rating for MDxHealth (NASDAQ:MDXH) - MarketBeat
BTIG reiterates Buy rating on MDxHealth stock, maintains $7 price target - Investing.com Australia
How MDxHealth SA stock benefits from tech adoptionMarket Sentiment Review & Capital Efficient Trading Techniques - Улправда
Why MDxHealth SA stock remains undervalued2025 Valuation Update & Weekly Watchlist for Consistent Profits - Улправда
Is MDxHealth SA stock overvalued by current metricsJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Retail Surge: How MDxHealth SA stock benefits from tech adoptionJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
Why MDxHealth SA stock is a must watch in 20252025 Growth vs Value & AI Powered Market Entry Ideas - DonanımHaber
Reviewing 111 (NASDAQ:YI) & MDxHealth (NASDAQ:MDXH) - Defense World
MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
MDxHealth management to meet virtually with BTIG - MSN
Finanzdaten der Mdxhealth Sa-Aktie (MDXH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):